RESUMO: "Produtos naturais inibidores da enzima acetilcolinesterase". A Doença de Alzheimer (DA) é uma patologia neurodegenerativa, progressiva, que afeta principalmente a população idosa, responsável por 50-60% dos casos de demência em pessoas com mais de 65 anos de idade. Os principais sintomas associado a DA envolve defi ciência orgânica cognitiva, principalmente perda de memória. Outras características associadas com os estágios avançados de DA inclui défi cit na linguagem, depressão, problemas de comportamento, inclusive agitação, alterações de humor e psicose.Um dos mais promissores caminhos para tratar esta doença é aumentar o nível de acetilcolina no cérebro usando inibidores da acetilcolinesterase (AChE). Este trabalho teve como objetivo revisar a literatura das plantas e substâncias encontradas nas plantas, inibidores da enzima acetilcolinesterase. Foram levantadas 309 plantas e 260 substâncias isoladas de plantas que foram classifi cados em grupos químicos adequados, os modelo testados, e suas atividades. Foram consultados 175 referências.
INTRODUCTION
The enzyme acetylcholinesterase (AChE) catalyses the hydrolysis of the ester bound of acetylcholine (ACh) to terminate the impulse transmitted action of ACh through cholinergic synapses (Stryer, 1995) . Although the basic reason of Alzheimer's disease (AD) is not clear so far, AD is fi rmly associated with impairment in cholinergic transmission. A number of AChE inhibitors have been considered as candidates for the symptomatic treatment of AD as the most useful relieving strategy (Howes et al., 2003) .
Reversible inhibitors of cholinesterase are currently used in clinical trials examining the treatment of Alzheimer's disease. Anticholinesterase may interact with the central cholinergic system to improve memory and cognitive defi cits of the patients by diminishing the breakdown of acetylcholine at the synaptic site in the brain. However, the therapeutic window is small, and testing of the inhibitory effect on acetylcholinesterase (AChE) in erythrocytes has been proposed as a guide to the effi cacy and safety of putative therapies.
Alzheimer's disease is a progressive degenerative neurologic disorder resulting in impaired memory and behavior. Epidemiological data indicate a potentially considerable increase in the prevalence of the disease over the next two decades (Johnson et al., 2000) . AD affects up to 5% of people over 65 years, rising to 20% of those over 80 years (Camps et al., 2000a) . Most treatment strategies have been based on the cholinergic hypothesis which postulated that memory impairments in patients suffering from this disease result from a defi cit of cholinergic function in brain. Cholinergic neurotransmission is specially affected in patients with Alzheimer's disease. One of the most promising approaches for treating this disease is to enhance the acetylcholine level in brain using acetylcholinesterase inhibitors (Enz et al., 1993) . Several AChE inhibitors are being investigated for the treatment of Alzheimer's disease. However, only tacrine (1), donezepil (2), rivastigmine (3) and galanthamine (4) have been approved by the Food and Drug Administration in the United States (Zarotsky et al., 2003) . Among the other strategies under investigation, monoamine oxidase B (MAO-B) inhibitors have also been proposed for the treatment of AD. Recent studies have shown that MAO-B activity can increase up to 3-fold in the temporal, parietal and frontal cortex of AD patients compared with controls. This increase in MAO-B activity produces an elevation of brain levels of hydroxyl radicals, which has been correlated with the development of Aβ plaques. Aβ is the main component of the senile plaques found in AD brains and any compound able to inhibit its aggregation might be regarded as potentially useful in the treatment of the disease (Bruhlmann et al., 2001) .
Nature is a rich source of biological and chemical diversity. The unique and complex structures of natural products cannot be obtained easily by chemical synthesis. A number of plants in the world have been used in traditional medicine remedies. Huperzine A (5) is a natural compound fi rst isolated from Chinese medicine Huperzia serrata (Thumb.) in 1986, is a potent, reversible and selective inhibitor of AChE.
In a previous paper this research group has reviewed crude plant extracts and chemically defi ned molecules with potential antitumor activity for mammary (Moura et al., 2001) , cervical (Moura et al., 2002) and ovarian neoplasias (Silva et al ., 2003) , as inhibitors of HMG CoA reductase (Gonçalves et al., 2000) , central analgesic activity (Almeida et al., 2001) , employed in prevention of osteoporosis (Pereira et al., 2002) , for the treatment of Parkinson's disease (Morais, 2003) , with antileishmanial (Rocha et al., 2005) , hypoglycaemic (Barbosa-Filho et al., 2005) and antiinfl ammatory activity (Falcão et al., 2005 , Barbosa-Filho et al., 2006 . The present work reviews the literature on plants and plant-derived compounds inhibitors of enzyme acetylcholinesterase.
MATERIALS AND METHODS
The keywords used for this review were medicinal plants, natural products, and acetylcholinesterase inhibitors. The search perfound using Chemical Abstracts, Biological Abstracts and the data bank of the University of Illinois at Chicago, NAPRALERT (Acronym for NAtural PRoducts ALERT), updated to December 2004. The references obtained were later consulted. 
RESULTS AND DISCUSSION
Consultation of various types of literature sources resulted in elaboration of a list of natural products (Table 1 and 2) evaluated specifi cally for acetylcholinesterase inhibition. It should be noted that most of references cited are not fi rst-hand observations, but secondary sources. For details on the models or mechanism-based bioassays utilized for selecting plant extracts and pure compounds against acetylcholinesterase, the original references should be consulted.
Plant extracts inhibitors of acetylcholinesterase enzyme
Acetylcholine is a neurotransmitter inhibited primarily by acetylcholinesterase (AChE) and secondly by butyrylcholinesterase (BChE), considered to play a role in the pathology of AD (Hebert et al., 1995) . Despite the unknown etiology of AD, elevation of acetylcholine amount through AChE enzyme inhibition has been accepted as the most effective treatment strategy against AD. Therefore, AChE inhibitors have become the remarkable alternatives in treatment of AD. However, the present drugs (tacrine, rivastigmine and donezepil) with AChE inhibitory activity possess some side effects (Schneider, 2001) . Consequently, it is compulsory to develop new drugs in order to combat AD (Viegas-Junior et al., 2004) .
The history of drug discovery showed that plants are highly rich sources in the search for new active compounds and they have become a challenge to modern pharmaceutical industry. Many synthetic drugs owe their origin to plant-based complementary medicine. Since AD, one of the most common cause of death worldwide, has become a threaten to public health, new treatment strategies based on medicinal plants have been focused (Howes et al., 2003; Orhan et al., 2004) .
A recent study with Brazilian plants showed excellent results for the species Amburana cearensis, Lippia sidoides, Paullinia cupana, Plathymiscium fl oribundum and Solanum asperum (Trevisan; Macedo, 2003) . Since the plants have been used in treatment of memory disfunction in some folk medicines since centuries the present study presents a review of 309 plants belong to 92 botanical families tested against acetylcholinesterase inhibition. The plants are listed in Table 1 , in alphabetical order of their family, scientifi c name, country, plant part used, type of extract, dose/ concentration, result and references.
Chemically-defi ned molecule as inhibitors of acetylcholinesterase enzyme
The prototype for the centrally acting AChE inhibitors was tacrine, the fi rst drug to be approved in the United States (Cognex ® ) for the treatment of AD.
However, its severe side effects such hepatotoxicity and gastrointestinal upset, represent an important drawback (Camps et al., 2000 Galanthamine, a long acting, selective, reversible and competitive AChE inhibitor, is considered to be more effective in the treatment of AD and to have fewer limitations (Rhee et al., 2001) . Recently it has reported wich because of bioavailability problems and possible side-effects, there still is great interest in fi nding better AChE inhibitors.
Donezepil was developed in order to overcome the disadvantages of physostigmine and tacrine, and later approved by the FDA for treatment of AD. It is highly selective for acetylcholinesterase with a signifi cantly lower affi nity for butyrylcholinesterase (Racchi et al., 2004) .
Rivastigmine is a carbamilating, pseudoirreversible acetylcholinesterase inhibitor which in preclinical biochemical studies has shown a signifi cant nervous system selectivity (Racchi et al., 2004) .
(-)-Huperzine A is a natural compound fi rst isolated from Chinese medicine Huperzia serrata (Thumb.) in 1986. It is a potent, reversible and selective inhibitor of AChE with a rapid absorption and penetration into the brain in animal tests. Compared to tacrine, physostigmine (6), galanthamine and donezepil, huperzine A possesses a longer duration of action and higher therapeutic index, and the peripheral cholinergic side effects are minimal at therapeutic doses (Camps et al., 2000; Li et al., 2004) . Huperzine A possesses higher selectivity and has almost no effect on butyrylcholinesterase. In China, huperzine A has already been approved as a palliative drug for AD (Högenauer et al., 2001) .
We founded 260 chemically defi ned natural molecules reported in the literature, which have been evaluated for acetylcholinesterase inhibition. The compounds tested, which have been isolated and identifi ed belong to the classes of alkaloids (139), monoterpenes (27), coumarins (18), triterpenes (17), fl avonoids (14), benzenoids (13), diterpenes (8), oxygen heterocycles (5), sesquiterpenes (5), stilbenes (3), lignans (2), sulfur compounds (2), proteids (2), polycyclic (1), quinoid (1), benzoxazinone (1), carotenoid (1) and alycyclic (1).
CONCLUSION
The present work shows that most of the plant extracts tested showed inhibitory activity against acetylcholinesterase and they could be considered for further studies in the treatment of AD. In particular, the species belonging to Amaryllidaceae, Apiaceae, Asteraceae, Fabaceae and Fumariaceae were the most studied. Since most of acetylcholinesterase inhibitors are known to contain nitrogen, the higher activity of these extracts may be due to their rich alkaloidal content. The alkaloids are the major compounds isolated from this species and shows inhibitory activity for the acetylcholinesterase. More research is needed to further explore the actions of this alkaloids in the search of promising treatment for AD. Cymene, para Funtumine, 
N-methyl

